HC Wainwright Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price

Key Points

• HC Wainwright raised BioMarin’s price target to $60 from $50 while maintaining a “neutral” rating, implying 2.38% downside from the prior close.
• BioMarin exceeded quarterly expectations with $1.20 EPS versus $0.95 expected and revenue of about $990 million, up 20% year over year. The company set fiscal 2026 EPS guidance at $4.90–$5.10.
• Analyst sentiment remains broadly positive, with MarketBeat reporting a consensus “Moderate Buy” rating and an average price target of $87.55; institutional investors own 98.71% of the stock.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its price target hoisted by equities researchers at HC Wainwright from $50.00 to $60.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the biotechnology company's stock. HC Wainwright's price target would indicate a potential downside of 2.38% from the company's previous close.

Other equities research analysts have also recently issued reports about the company. Oppenheimer restated an "outperform" rating on shares of BioMarin Pharmaceutical in a research note on Friday. Bank of America decreased their price target on BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating on the stock in a research note on Tuesday, May 19th. Citigroup boosted their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Royal Bank Of Canada dropped their price objective on BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised BioMarin Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.55.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $61.46 on Friday. The company's 50-day moving average price is $58.06 and its two-hundred day moving average price is $57.01. The firm has a market cap of $11.88 billion, a P/E ratio of 44.86, a P/E/G ratio of 0.46 and a beta of 0.24. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $66.28.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 8.29% and a return on equity of 6.50%. The firm's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, analysts anticipate that BioMarin Pharmaceutical will post 4.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BMRN. Activest Wealth Management bought a new stake in BioMarin Pharmaceutical during the 4th quarter worth $26,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BioMarin Pharmaceutical in the second quarter valued at about $39,000. CIBC Private Wealth Group LLC boosted its stake in shares of BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at about $40,000. Finally, Parallel Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 295 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported second-quarter adjusted earnings of $1.20 per share, exceeding the $0.95–$0.96 analyst consensus. Revenue rose 20% year over year to approximately $990 million, well above expectations of roughly $932 million. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company raised its full-year 2026 adjusted diluted EPS guidance to $4.90–$5.10, above the prior analyst consensus of about $4.80. Management also cited stronger growth expectations for total revenue and VOXZOGO. BioMarin Pharmaceutical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management said the addition of GALAFOLD and POMBILITI plus OPFOLDA, together with expected cost synergies, should accelerate revenue growth, improve EPS, expand operating margins and increase operating cash flow through the mid-2030s. BioMarin Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the earnings beat, quarterly EPS declined from $1.44 in the year-earlier period to $1.20, which may temper enthusiasm about near-term profitability. Full-year revenue guidance of approximately $3.9 billion was broadly in line with consensus rather than a major upside surprise. Compared to Estimates, BioMarin Q2 Earnings: A Look at Key Metrics

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source